PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsX-SCID gene therapy cancer risk in mice

BioNews

X-SCID gene therapy cancer risk in mice

Published 9 June 2009 posted in News and appears in BioNews 356

Author

BioNews

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Replacement genes used to treat an inherited immune disorder could trigger cancer, new research carried out on rodents suggests. The study, published in the journal Nature, shows that treating mice with a normal copy of the gene defective in X-linked severe combined immune deficiency (X-SCID) results in cancer of the...

Replacement genes used to treat an inherited immune disorder could trigger cancer, new research carried out on rodents suggests. The study, published in the journal Nature, shows that treating mice with a normal copy of the gene defective in X-linked severe combined immune deficiency (X-SCID) results in cancer of the white blood cells in a third of the animals. The scientists say that the study highlights the need for longer-term follow-up in studies designed to test the safety of new gene therapy treatments. However, UK gene therapy researcher Adrian Thrasher says that the results could have been caused by artificially high levels of the gene in the animals.


The team, based at the Salk Institute for Biological Studies in La Jolla, California, say their findings could help explain one of the three cases of leukaemia in a French X-SCID gene therapy trial. Two of the cases are thought to have arisen after the therapeutic gene activated a gene known to be involved in cancer, but the new study suggests that the therapeutic gene itself may also pose a risk. The researchers followed mice treated with the IL2RG gene - which is missing or faulty in people affected by X-SCID - and followed them up for 18 months, three times longer than any previous study. They found that a third of the animals developed cancer of the white blood cells, at an average age of ten months. 'These results suggest that curing X-SCID by replacing IL2RG in the manner it is currently being done puts patients at an increased risk of developing cancer', said team member Niels-Bjarne Woods.


Ten patients affected by X-SCID have so far been treated in the French trial, based at the Necker Hospital in Paris. While most have responded extremely well to the therapy, the trial was halted for a second time in January 2005, after a third patient developed symptoms of leukaemia. Two of the affected boys are now in remission, but the other died, and the trial is currently continuing on a case-by-case basis. Children affected by SCID have a faulty gene that means they have no working immune system, so their bodies cannot fight infections. This life-threatening condition is sometimes called 'bubble boy' disease as, unless they can be successfully treated with a matched bone marrow transplant, patients must spend their lives in a sterile environment.


Woods says that the new study could help explain the occurrence of leukaemia in one of the French patients, in whom the therapeutic gene did not activate a cancer-causing gene. In the affected mice, the IL2RG gene inserted itself at different places in the animals' DNA, ruling out the possibility that any cancer genes had been activated. The fact that the leukaemia did not appear until 2-3 years after the gene therapy treatment suggests that 'preclinical experimental treatments involving transgenes should include long-term follow-up before entering a clinical trial', says Woods. He also says that replacing a faulty gene that has multiple effects in the body may prove much more problematic than replacing a gene with a single main role.


Mark Kay, a US gene therapist based at Stanford University says that 'the results are significant and need to be considered in the design of future gene therapies'. However, he also sees a continuing need for SCID trials for patients with no other treatment options, ScienceNOW reports. But UK researcher Adrian Thrasher told the Daily Telegraph newspaper that the data is 'very preliminary', and the effects could be down to 'artificially high levels of the gene in the animals'. Thrasher, who runs the X-SCID trial based at Great Ormond Street Hospital in London, added that 'certainly we and our colleagues have found no evidence for this effect'.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 November 2017 • 2 minutes read

NHS will fund gene therapy for bubble boy syndrome

by Jen Willows

NICE has approved a gene therapy for children with a rare disorder that leaves them with no functioning immune system...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 October 2014 • 2 minutes read

Revamped gene therapy for 'bubble boy' immune condition does well in trial

by Dr Jamie Heather

Gene therapy to treat children with 'bubble boy syndrome' seems to be both safe and effective, a study published in the New England Journal of Medicine has found...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
22 November 2012 • 2 minutes read

No immune system? No problem: Gene therapy found for 'bubble babies'

by Rosemary Paxman

Over a dozen children with 'boy in bubble' syndrome are alive and well, with functioning immune systems, nine years after undergoing gene therapy to correct their disorder, researchers report....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 May 2011 • 1 minute read

xFrench gene therapy success

by BioNews

A report in last week's New England Journal of Medicine shows that children treated by gene therapy at the Necker Hospital for Sick Children in Paris, France, are still living normal lives after more than two years. Four boys were successfully treated in the French study, all having the X-linked...

PET BioNews
News
12 November 2010 • 1 minute read

Cord blood used to treat infant with SCID

by Christopher Chatterton

Doctors from Great Ormond Street Hospital (GOSH) have used stem cells from donated cord blood to treat a child with a rare genetic disorder....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 1 minute read

Gene therapy trial for immune disorder hailed a success

by Dr Megan Allyse

Researchers in Italy and Israel have announced that they have successfully used gene therapy to treat ten children who suffer from a rare form of severe combined immunodeficiency (SCID) called ADA-SCID. The trial marks one of the first successful uses of gene therapy since past trials of...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Gene therapy trials under review following third cancer case

by BioNews

The US Food and Drug Administration (FDA) has recommended that gene therapy treatments for an inherited immune disorder are limited to those who have no alternative. The move follows news that a third child in a similar French trial has developed leukaemia. The trial for X-linked severe combined immunodeficiency disorder...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 1 minute read

French gene therapy trial suspended again

by BioNews

A gene therapy trial for an inherited immune deficiency disorder has been suspended again, following the appearance of complications in a third child. Eleven patients affected by X-linked severe combined immunodeficiency disorder (X-SCID) have so far been treated by the team, based at the Necker Hospital in Paris. While most...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

More successes for gene therapy treatment

by BioNews

Four children who received gene therapy for a severe inherited immune disorder are now all at home living normal lives, UK scientists report. The boys, who were affected by severe combined immunodeficiency (SCID), received the pioneering treatment at Great Ormond Street Hospital in London. In a commentary accompanying the study...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Good news for gene therapy

by BioNews

A French gene therapy trial halted after two participants developed leukaemia looks set to restart after a 22-month suspension, reports Nature. Scientists at the Necker hospital in Paris successfully treated nine children with an inherited immune system disorder called X-linked severe combined immune deficiency (X-SCID). But the trial, along...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« European court denies UK prisoner's IVF request

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

6 July 2022 • 1 minute read

Frozen embryo transfers linked to high blood pressure in pregnancy

5 July 2022 • 1 minute read

Anorexia in pregnancy linked to increased risk of complications

5 July 2022 • 2 minutes read

Pregnancy after breast cancer treatment does not increase risk of recurrence

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856